moxifloxacin has been researched along with framycetin in 3 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (framycetin) | Trials (framycetin) | Recent Studies (post-2010) (framycetin) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 8,151 | 460 | 653 |
Protein | Taxonomy | moxifloxacin (IC50) | framycetin (IC50) |
---|---|---|---|
30S ribosomal protein S6 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 0.032 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 0.032 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 0.032 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Xu, Z | 1 |
Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF | 1 |
1 review(s) available for moxifloxacin and framycetin
Article | Year |
---|---|
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; Drug Design; Methicillin-Resistant Staphylococcus aureus; Triazoles | 2020 |
2 other study(ies) available for moxifloxacin and framycetin
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim | 2022 |